Skip to content
Important: This site presents data from the FDA Adverse Event Reporting System (FAERS). A report does not mean the drug caused the event. Full disclaimer.

Does TOFACITINIB Cause Acute myocardial infarction? 117 Reports in FDA Database

Grow Your Own Natural Pharmacy at Home

Medicinal Garden Kit — 10 healing herbs, 4,818 seeds + step-by-step guide.

Get the Kit

According to the FDA Adverse Event Reporting System (FAERS), 117 reports of Acute myocardial infarction have been filed in association with TOFACITINIB (XELJANZ XR). This represents 0.1% of all adverse event reports for TOFACITINIB.

117
Reports of Acute myocardial infarction with TOFACITINIB
0.1%
of all TOFACITINIB reports
23
Deaths
77
Hospitalizations

How Dangerous Is Acute myocardial infarction From TOFACITINIB?

Of the 117 reports, 23 (19.7%) resulted in death, 77 (65.8%) required hospitalization, and 18 (15.4%) were considered life-threatening.

Is Acute myocardial infarction Listed in the Official Label?

This adverse event is not currently listed in the official FDA drug label for TOFACITINIB. However, 117 reports have been filed with the FAERS database.

What Other Side Effects Does TOFACITINIB Cause?

Drug ineffective (30,382) Pain (21,659) Condition aggravated (16,925) Arthralgia (15,640) Fatigue (13,551) Rheumatoid arthritis (12,277) Off label use (11,736) Headache (11,061) Joint swelling (10,686) Malaise (9,040)

What Other Drugs Cause Acute myocardial infarction?

ROSIGLITAZONE (2,437) TESTOSTERONE (871) ASPIRIN (826) CLOPIDOGREL BISULFATE (624) CALCIUM\DEXTROSE\MAGNESIUM\SODIUM\SODIUM (521) TICAGRELOR (442) RIVAROXABAN (375) METFORMIN (370) LENALIDOMIDE (354) METFORMIN\ROSIGLITAZONE (351)

Which TOFACITINIB Alternatives Have Lower Acute myocardial infarction Risk?

TOFACITINIB vs TOFERSEN TOFACITINIB vs TOLNAFTATE TOFACITINIB vs TOLODODEKIN ALFA TOFACITINIB vs TOLTERODINE TOFACITINIB vs TOLVAPTAN

Related Pages

TOFACITINIB Full Profile All Acute myocardial infarction Reports All Drugs Causing Acute myocardial infarction TOFACITINIB Demographics